Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Equity Average (2021 - 2025)

Historic Equity Average for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $111.3 million.

  • Prime Medicine's Equity Average fell 4232.45% to $111.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.3 million, marking a year-over-year decrease of 4232.45%. This contributed to the annual value of $143.1 million for FY2024, which is 3630.23% down from last year.
  • Per Prime Medicine's latest filing, its Equity Average stood at $111.3 million for Q3 2025, which was down 4232.45% from $83.9 million recorded in Q2 2025.
  • Prime Medicine's 5-year Equity Average high stood at $297.5 million for Q1 2023, and its period low was -$209.1 million during Q3 2022.
  • For the 5-year period, Prime Medicine's Equity Average averaged around $87.8 million, with its median value being $146.8 million (2023).
  • In the last 5 years, Prime Medicine's Equity Average soared by 28412.88% in 2023 and then tumbled by 6189.8% in 2025.
  • Quarter analysis of 5 years shows Prime Medicine's Equity Average stood at -$125.3 million in 2021, then soared by 137.17% to $46.6 million in 2022, then surged by 250.99% to $163.5 million in 2023, then increased by 4.78% to $171.3 million in 2024, then tumbled by 35.01% to $111.3 million in 2025.
  • Its Equity Average was $111.3 million in Q3 2025, compared to $83.9 million in Q2 2025 and $130.0 million in Q1 2025.